Clopidogrel in addition to aspirin reduces in-hospital major cardiac and cerebrovascular events in unselected patients with acute ST segment elevation myocardial

Summary

We sought to assess the effect of clopidogrel on in-hospital events in unselected patients with acute ST elevation myocardial infarction (STEMI). In a retrospective analysis of consecutive patients enrolled in the Acute Coronary Syndromes (ACOS) registry with acute STEMI we compared outcomes of either adjunctive therapy with aspirin alone or aspirin plus clopidogrel within 24 hours after admission. A total of 7,559 patients were included in this analysis, of whom 3,541 were treated with aspirin alone, and 4,018 with dual antiplatelet therapy. The multivariable analysis with adjustment for baseline characteristics and treatments showed that the rate of in-hospital MACCE (death, non-fatal reinfarction, non-fatal stroke) was significantly lower in the aspirin plus clopidogrel group, compared to the aspirin alone group in the entire cohort and all three reperfusion strategy groups (entire group odds ratio 0.60, 95% CI 0.49–0.72, no reperfusion OR 0.69,95% CI 0.51–0.94,fibrinolysis OR 0.62,95% CI 0.44–0.88, primary PCI OR 0.54, 95% CI 0.39–0.74).There was a significant increase in major bleeding complications with clopidogrel (7.1% vs. 3.4%, p<0.001). In clinical practice early adjunctive therapy with clopidogrel in addition to aspirin in patients with STEMI is associated with a significant reduction of in-hospital MACCE regardless of the initial reperfusion strategy. This advantage was associated with an increase in major bleeding complications.

Keywords

Clopidogrel - reperfusion therapy - primary percutaneous coronary intervention - ST elevation myocardial infarction - prognosis - clinical practice

 

• References

• 1 Van de Werf F, Ardissino D, Betriu A. et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003; 24: 28-66.
• 2 ISIS 2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected myocardial infarction. Lancet 1988; 2: 349-360.
• 3 Herbert JM, Frechel D, Valler E. et al. Clopidogrel, a novel antiplatelet and antithrombotic drug. Cardiovasc Drug Rev 1993; 11: 180-198.
• 4 The CURE Investigators. Effects of clopidogrel in addition to aspirin in patients with acue coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
• 5 Steinhubl SR, Berger PB, Mann JT. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-2420.
• 6 Sabatine MS, Cannon CP, Gibson CM. et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-1189.
• 7 COMMIT collobarative group.. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-1621.
• 8 Sabatine MS, Cannon CP, Gibson CM. et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with St-elevation myocardial infarction. The PCI-CLARITY Study. JAMA 2005; 294: 1224-1232.
• 9 Zeymer U, Senges J. Qualitätsregister in der Kardiologie. Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2004; 47: 533-539.
• 10 Zeymer U, Gitt AK, Junger C. et al. and the Acute COronary Syndromes (ACOS) registry investigators. Effect of clopidogrel on 1-year mortality in hospital survivors of acute ST-segment elevation myocardial infarction in clinical practice. Eur Heart J 2006; 27: 2661-2666.
• 11 Morrow DA, Antman EM, Charlesworth A. et al. TIMI risk score for St-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an InTIME II trial substudy. Circulation 2000; 102: 2031-2037.
• 12 Steinhubl SR, Kastrati A, Berger P. Variation in the definitions of bleeding in clinical trials of patients with acute coronary syndromes and undergoing percutaneous coronary intervention and its impact on the apparent safety of antithrombotic drugs. Am Heart J 2007; 154: 3-11.